These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies. von Maltitz P; Wettstein L; Weil T; Schommers P; Klein F; Münch J J Virol; 2024 Apr; 98(4):e0119023. PubMed ID: 38501840 [TBL] [Abstract][Full Text] [Related]
10. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex. Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335 [TBL] [Abstract][Full Text] [Related]
11. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. Sagar M; Akiyama H; Etemad B; Ramirez N; Freitas I; Gummuluru S J Infect Dis; 2012 Apr; 205(8):1248-57. PubMed ID: 22396600 [TBL] [Abstract][Full Text] [Related]
12. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259 [TBL] [Abstract][Full Text] [Related]
13. Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure. Suphaphiphat K; Desjardins D; Lorin V; Dimant N; Bouchemal K; Bossevot L; Galpin-Lebreau M; Dereuddre-Bosquet N; Mouquet H; Le Grand R; Cavarelli M Nat Commun; 2023 Oct; 14(1):6224. PubMed ID: 37803011 [TBL] [Abstract][Full Text] [Related]
14. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476 [TBL] [Abstract][Full Text] [Related]
15. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712 [TBL] [Abstract][Full Text] [Related]
16. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583 [TBL] [Abstract][Full Text] [Related]
17. Bystander CD4 T-cell death is inhibited by broadly neutralizing anti-HIV antibodies only at levels blocking cell-to-cell viral transmission. Luo X; Mouquet H; Schwartz O; Greene WC J Biol Chem; 2021 Oct; 297(4):101098. PubMed ID: 34418431 [TBL] [Abstract][Full Text] [Related]